Regence BlueShield of Idaho prior authorization, page 11

CPT code lookup

Each row is one code from the public prior authorization list. The description is the procedure or service name on that source row. This is not a coverage decision.

Prior authorization codes

Prior authorization codes
CodeDescriptionSource
0239UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0242UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0326UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0409UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0485UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0487UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0530UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0539UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0562UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0571UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0585UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
0631UCirculating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
81462Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
81463Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
81464Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor CancersCommercial Pre-authorization List, Pg 1 Original policy
81595Laboratory Tests for Organ Transplant RejectionCommercial Pre-authorization List, Pg 1 Original policy
80145Measurement of Serum Antibodies to Selected Biologic AgentsCommercial Pre-authorization List, Pg 1 Original policy
80230Measurement of Serum Antibodies to Selected Biologic AgentsCommercial Pre-authorization List, Pg 1 Original policy
80280Measurement of Serum Antibodies to Selected Biologic AgentsCommercial Pre-authorization List, Pg 1 Original policy
A4100Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
A6460Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
A6461Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
G0681Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
G0682Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
G0683Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
G0684Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4101Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4102Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4105Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4107Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4114Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4116Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4121Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4122Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4128Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4132Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4133Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4151Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4154Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4159Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4160Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4186Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4187Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4391Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4431Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4432Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
Q4433Bioengineered Skin and Soft Tissue Substitutes and Amniotic ProductsCommercial Pre-authorization List, Pg 1 Original policy
32701Charged-Particle (Proton) RadiotherapyCommercial Pre-authorization List, Pg 1 Original policy
61796Charged-Particle (Proton) RadiotherapyCommercial Pre-authorization List, Pg 1 Original policy
61797Charged-Particle (Proton) RadiotherapyCommercial Pre-authorization List, Pg 1 Original policy

Sources

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.